programas cribado cancer


Nota Bibliográfica

Esta Nota es una recopilación de publicaciones (artículos, informes, libros) sobre cribado de cáncer resultado de una revisión no sistemática de la literatura.

Podéis dirigir vuestros comentarios o sugerencias sobre la Nota a:

Josep A Espinás. Pla Director d'Oncología de Catalunya.
Correo electrónico: Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla

Nota bibliográfica cribado c cérvix 2014-03

Xue X, Kim MY, Castle PE, Strickler HD. A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example. J Clin Epidemiol. 2014;67(3):343–53. Available from: doi: 10.1016/j.jclinepi.2013.09.013. PMID: 24332397.
CONCLUSION: The proposed approach is an easy to apply and accurate method for addressing verification bias in studies of multiple screening methods


Nota bibliográfica cribado c cérvix 2014-02

Wentzensen N, Schiffman M. Filling a gap in cervical cancer screening programmes. Lancet Oncol. 2014;(0). Available from: doi:

Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83. Available from: doi:

Interpretation In screening programmes using signal-based assays, sampling by a clinician should be recommended. However, HPV testing on a self-sample can be suggested as an additional strategy to reach women not participating in the regular screening programme. Some PCR-based HPV tests could be considered for routine screening after careful piloting assessing feasibility, logistics, population compliance, and costs.

Dickinson JA, Miller AB, Popadiuk C. When to start cervical screening: epidemiological evidence from Canada. BJOG An Int J Obstet Gynaecol. 2014;121(3):255–60. Available from: doi: 10.1111/1471-0528.12484


Nota bibliográfica cribado c cérvix 2014-01

Mahmud SM, Kliewer E V, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the Quadrivalent Human Papillomavirus Vaccine Against Cervical Dysplasia in Manitoba, Canada. J Clin Oncol. 2014; Available from: doi: 10.1200/JCO.2013.52.4645.

Purpose Effectiveness of the quadrivalent human papillomavirus (QHPV) vaccine Conclusion A significant percentage of vaccinated women may not be protected against HSIL and lesser dysplasia especially if they were vaccinated at older age (≥ 18) or had abnormal cytology before vaccination. These findings affirm the importance of vaccination before any significant exposure to HPV occurs and underscore the need for screening programs that cover all sexually active women, even if they were vaccinated.

Harper DM, Groner JA. Positive High-Risk HPV Test with Negative Cytology—A Conundrum and Blessing of Our Latest Technology. Cancer Epidemiol Biomarkers Prev. 2014;23(1):10–1. Available from: doi: 10.1158/1055-9965.EPI-13-0708.

Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DAM, Snijders PJF, et al. Primary hrHPV DNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. Cancer Epidemiol Biomarkers Prev. 2014;23(1):55–63. Available from: doi: 10.1158/1055-9965.EPI-13-0173.

Conclusions: Triaging hrHPV-positive women by cytology at baseline and after 6 to 12 months, possibly in combination with baseline HPV16/18 genotyping, seems acceptable for cervical cancer screening.Impact: Implementable triage strategies are provided for primary hrHPV screening in an organized setting. Cancer Epidemiol Biomarkers Prev; 23(1); 55–63. ©2013 AACR.

Dijkstra MG, Snijders PJF, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJLM. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol. 2014; Available from: doi: 10.1093/annonc/mdt538.

 Cytology-based nation-wide cervical screening has led to a substantial reduction of the incidence of cervical cancer in western countries. However, the sensitivity of cytology for the detection of high-grade precursor lesions or cervical cancer is limited; therefore, repeated testing is necessary to achieve program effectiveness. Additionally, adenocarcinomas and its precursors are often missed by cytology. Consequently, there is a need for a better screening test. The insight that infection with high-risk human papillomavirus (hrHPV) is the causal agent of cervical cancer and its precursors has led to the development of molecular tests for the detection of hrHPV. Strong evidence now supports the use of hrHPV testing in the prevention of cervical cancer. In this review, we will discuss the arguments in favor of, and concerns on aspects of implementation of hrHPV testing in primary cervical cancer screening, such as the age to start hrHPV-based screening, ways to increase screening attendance, requirements for candidate hrHPV tests to be used, and triage algorithms for screen-positive women.

Castañón A, Landy R, Cuzick J, Sasieni P. Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. Franco EL, editor. PLoS Med. 2014;11(1):e1001585. Available from: doi: 10.1371/journal.pmed.1001585.

Conclusions: Women with adequate negative screening at age 50–64 y had one-sixth of the risk of cervical cancer at age 65–83 y compared with women who were not screened. Stopping screening between ages 60 and 69 y in women with adequate negative screening seems sensible, but further screening may be justifiable as life expectancy increases.

Rositch AF, Silver MI, Gravitt PE. Cervical cancer screening in older women: new evidence and knowledge gaps. PLoS Med. 2014;11(1):e1001586. Available from: doi: 10.1371/journal.pmed.1001586. PMID: 24453947.

Anne Rositch and colleagues discuss the study by Peter Sasieni and colleagues on cervical cancer screening in older women and describe the further information needed to help inform decisions about whether to extend screening programs beyond 65 years for women with adequate negative screening. Please see later in the article for the Editors’ Summary.

Burki TK. Cervical cancer: screening and risk with age. Lancet Oncol. (0). Available from: doi:


Nota bibliográfica cribado c cérvix 2013-12

Ogilvie GS, Smith LW, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, et al. Women’s intentions to receive cervical cancer screening with primary human papillomavirus testing. Int J Cancer. 2013;133(12):2934–43. Available from: doi: 10.1002/ijc.28324. PMID: 23754203.

Use of primary HPV testing may optimize the screening paradigm, but programs should ensure robust planning and education to mitigate any negative impact on screening attendance rates.

Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133(11):2681–7. Available from: doi: 10.1002/ijc.28283. PMID: 23712523.

Offering self-sampling increased participation rates while the use of HPV testing increased the detection of cervical lesions (≥CIN2) in comparison to the group of women receiving a second invitation for a Pap-smear. However, low compliance to follow-up in the self-sampling group reduces the effectiveness of this screening approach in nonattenders women and must be carefully managed.

Schiffman M, Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med. 2013;369(24):2324–31. Available from: doi: 10.1056/NEJMcp1210379. PMID: 24328466


Nota bibliográfica cribado c cérvix 2013-11

*Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. Lancet. 2013;6736(13):10–1. Available from: doi: 10.1016/S0140-6736(13)62028-0.

*Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer : follow-up of four European randomised controlled trials. Lancet. 2013;39(13):1–9. Available from: doi: 10.1016/S0140-6736(13)62218-7.
Interpretation HPV-based screening provides 60—70% greater protection against invasive cervical carcinomas compared with cytology. Data of large-scale randomised trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years.

García-Garrido AB, Vázquez-Rodríguez JA, Grande-González E, Ramos-Barrón MÁ. [Coverage and costs of opportunistic screening for cervical cancer in Cantabria (Spain).]. Gac Sanit. 2013;(xx):6–11. Available from: doi: 10.1016/j.gaceta.2013.05.007. PMID: 23845269.
CONCLUSIONS: Only 26% of women in Cantabria attended screening within the intervals recommended in the current opportunistic protocol. The cost data provided in this study may be useful for future economic evaluations.

Rodríguez-Salés V, Roura E, Ibáñez R, Peris M, Bosch FX, Coma E E, et al. [Coverage of cervical cancer screening in Catalonia, Spain (2008-2011).]. Gac Sanit. 2013;(xx). Available from: doi: 10.1016/j.gaceta.2013.05.009. PMID: 23916983.
CONCLUSIONS: Cervical screening coverage in the National Health Service of Catalonia includes one in three women. Second round participation was poor. Existing computer systems in primary care centers can ensure monitoring of population-based screening programs for cervical cancer. These systems could be used to plan an organized screening program to ensure wider coverage and better follow-up


Página 1 de 11

web desarrollada y mantenida por :